Jason P. Rhodes

Filings by Jason P. Rhodes span 4 companies, the busiest being Dyne Therapeutics, Inc., Replimune Group, Inc. and Generation Bio Co. Over a trading history stretching from 6 January 2014 to 14 August 2026, the count stands at 253 filings.

In open-market terms, that means 2 purchases worth €23.0M on one side and 226 sales worth €185.7M on the other. The net balance comes to €162.7M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 16 option exercises. In 2026 alone, the filings show no purchases and 67 sales.

Most recently, on 17 August 2026, the filings show an open-market sale worth €6.1M in Dyne Therapeutics, Inc. The last purchase on record was published on 14 December 2022, which is 1,411 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.